BC Week In Review | Feb 1, 2019
Company News

Seelos closes reverse-merger with Apricus

Seelos Therapeutics Inc. (NASDAQ:SEEL) closed its previously announced reverse-merger with Apricus Biosciences Inc. (see "CNS Company Seelos Reverse Merging with Apricus" ). Seelos' pipeline includes SLS-002, an intranasal racemic ketamine in development to treat posttraumatic...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BC Week In Review | Aug 31, 2018
Company News

CNS company Seelos reverse merging with Apricus

Seelos Therapeutics Inc. (New York, N.Y.) will reverse-merge with Apricus Biosciences Inc. (NASDAQ:APRI). Seelos shareholders are expected to own about 86% of the merged company. Apricus shareholders are expected to own the remaining 14%, and...
BC Week In Review | Feb 23, 2018
Clinical News

Apricus get CRL for ED candidate Vitaros

Apricus Biosciences Inc. (NASDAQ:APRI) said it received a complete response letter to a resubmitted NDA for Vitaros alprostadil to treat erectile dysfunction. The company said FDA cited CMC and safety concerns specific to the 2.5%...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Sep 29, 2017
Clinical News

FDA accepts resubmitted NDA for Apricus' Vitaros

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc. (NASDAQ:APRI) to treat erectile dysfunction. The PDUFA date is Feb. 17, 2018. Vitaros is a topical prostaglandin E1 (PGE1) cream formulated...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 21, 2017
Financial News

Apricus completes follow-on

On April 21, urology and rheumatology company Apricus Biosciences Inc. (NASDAQ:APRI) raised $7 million through the sale of 5 million units at $1.40 in a follow-on underwritten by H.C. Wainwright. Each unit comprises a share...
BC Week In Review | Mar 31, 2017
Financial News

Apricus proposes follow-on

Urology and rheumatology company Apricus Biosciences Inc. (NASDAQ:APRI) proposed to raise up to $6.9 million in a follow-on underwritten by H.C. Wainwright on March 30. Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif.  ...
BC Week In Review | Mar 17, 2017
Company News

Apricus, Ferring deal

Apricus sold to Ferring remaining ex-U.S. rights and assets related to erectile dysfunction drug Vitaros alprostadil for $11.5 million upfront, plus up to $700,000 for product inventory and up to $500,000 for transition assistance. Ferring...
Items per page:
1 - 10 of 235
BC Week In Review | Feb 1, 2019
Company News

Seelos closes reverse-merger with Apricus

Seelos Therapeutics Inc. (NASDAQ:SEEL) closed its previously announced reverse-merger with Apricus Biosciences Inc. (see "CNS Company Seelos Reverse Merging with Apricus" ). Seelos' pipeline includes SLS-002, an intranasal racemic ketamine in development to treat posttraumatic...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BC Week In Review | Aug 31, 2018
Company News

CNS company Seelos reverse merging with Apricus

Seelos Therapeutics Inc. (New York, N.Y.) will reverse-merge with Apricus Biosciences Inc. (NASDAQ:APRI). Seelos shareholders are expected to own about 86% of the merged company. Apricus shareholders are expected to own the remaining 14%, and...
BC Week In Review | Feb 23, 2018
Clinical News

Apricus get CRL for ED candidate Vitaros

Apricus Biosciences Inc. (NASDAQ:APRI) said it received a complete response letter to a resubmitted NDA for Vitaros alprostadil to treat erectile dysfunction. The company said FDA cited CMC and safety concerns specific to the 2.5%...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Sep 29, 2017
Clinical News

FDA accepts resubmitted NDA for Apricus' Vitaros

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc. (NASDAQ:APRI) to treat erectile dysfunction. The PDUFA date is Feb. 17, 2018. Vitaros is a topical prostaglandin E1 (PGE1) cream formulated...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 21, 2017
Financial News

Apricus completes follow-on

On April 21, urology and rheumatology company Apricus Biosciences Inc. (NASDAQ:APRI) raised $7 million through the sale of 5 million units at $1.40 in a follow-on underwritten by H.C. Wainwright. Each unit comprises a share...
BC Week In Review | Mar 31, 2017
Financial News

Apricus proposes follow-on

Urology and rheumatology company Apricus Biosciences Inc. (NASDAQ:APRI) proposed to raise up to $6.9 million in a follow-on underwritten by H.C. Wainwright on March 30. Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif.  ...
BC Week In Review | Mar 17, 2017
Company News

Apricus, Ferring deal

Apricus sold to Ferring remaining ex-U.S. rights and assets related to erectile dysfunction drug Vitaros alprostadil for $11.5 million upfront, plus up to $700,000 for product inventory and up to $500,000 for transition assistance. Ferring...
Items per page:
1 - 10 of 235